Lessons from early large-scale adoption of celecoxib and rofecoxib by Australian general practitioners

• Department of Medicine, University of Queensland, Mater Health Services’ Adult Hospital, South Brisbane, QLD 4101.

---

• 1. Kerr S, Mant A, Horn F, et al. Lessons from early large-scale adoption of celecoxib and rofecoxib by Australian general practitioners. Med J Aust 2003; 179: 403-407. <eMJA full text>
• 2. MacDonald T, Morant S, Goldstein J, et al. Channelling bias and the incidence of gastrointestinal haemorrhage in users of meloxicam, coxibs, and older, non-specific non-steroidal anti-inflammatory drugs. Gut 2003; 52: 1265-1270.
• 3. Dowden J. Coax, COX and cola [editorial]. Med J Aust 2003; 179: 397-398. <eMJA full text>
• 4. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study. A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000; 284: 1247-1255.
• 5. Solomon D, Glynn R, Bohn R, et al. The hidden cost of nonselective nonsteroidal antiinflammatory drugs in older patients. J Rheumatol 2003; 30: 792-798.